Mesothelioma Clinical Trials Compared: How 8 Active Studies Stack Up in 2026

The 2026 mesothelioma clinical trial landscape features over 30 active studies spanning immunotherapy, targeted therapy, CAR-T cells, cancer vaccines, and proton beam radiation—the most diversified treatment pipeline in the disease's history. The CheckMate 743 five-year update confirmed a 14% long-term survival rate with immunotherapy versus 6% with chemotherapy, while new Phase III trials are recruiting patients for next-generation treatments.^[1][9]

Key Facts About Mesothelioma Clinical Trials in 2026

• CheckMate 743 five-year update: 14% OS (immunotherapy) vs 6% (chemotherapy), HR 0.74^[1]
• Non-epithelioid five-year survival: 12% vs 1% (HR 0.48)—immunotherapy's strongest subgroup benefit^[1]
• eVOLVE-Meso (NCT06097728): Phase III, ~825 patients, bispecific antibody volrustomig^[3]
• ATOMIC-Meso: first targeted therapy for non-epithelioid, OS 9.3 vs 7.7 months (HR 0.71, p=0.02)^[2]
• IND.227: pembrolizumab + chemo achieved 17.3-month OS and 62% ORR^[4]
• Perioperative immunotherapy: dual nivo+ipi arm showed 28.6-month median OS in resectable disease^[5]
• UV1 vaccine: 31% ORR with pembrolizumab vs 16% alone; FDA Fast Track granted^[7]
• CAR-T cell therapy: intrapleural delivery trials active at University of Pennsylvania and NCI^[6]
• Genetic profiling: BAP1 loss (60–80%), MTAP deletion (~25%), NF2 mutation (~40%) now open trial eligibility^[7]
• HIT-Meso: first Phase III proton beam therapy trial for mesothelioma, recruiting in the UK^[10]
• Approximately 3,000 new U.S. mesothelioma cases are diagnosed annually^[9]

What Did the CheckMate 743 Five-Year Update Reveal?

The February 2026 five-year update of CheckMate 743, published in the Journal of Clinical Oncology by Scherpereel et al., provides the longest follow-up data ever reported for first-line immunotherapy in pleural mesothelioma. At 66.8 months median follow-up across 605 patients, the results confirmed durable benefit from nivolumab plus ipilimumab.^[1]

Outcome	Immunotherapy	Chemotherapy	Hazard Ratio
5-Year Overall Survival	14%	6%	0.74 (CI: 0.62–0.88)
5-Year OS (Epithelioid)	14%	8%	0.85 (CI: 0.69–1.03)
5-Year OS (Non-Epithelioid)	12%	1%	0.48 (CI: 0.33–0.68)
5-Year PFS	8%	0%	—
Ongoing Response at 5 Years	17% of responders	0%	—

The non-epithelioid finding is the standout result. Patients with sarcomatoid and biphasic subtypes—historically the most treatment-resistant—achieved 12% five-year survival with immunotherapy compared to just 1% with chemotherapy. A biomarker analysis found that high baseline monocytic myeloid-derived suppressor cells (M-MDSCs) predicted poorer outcomes on immunotherapy (HR 1.25).^[1]

> "The five-year CheckMate 743 data confirm what we've been seeing in our clients: immunotherapy produces genuine long-term survivors in mesothelioma. One in seven patients treated with nivolumab plus ipilimumab is alive at five years. For non-epithelioid patients who previously had almost no options, the 12% versus 1% survival gap is transformative." > — David Foster, Executive Director of Client Services, Danziger & De Llano

Which Phase III Trials Are Actively Recruiting Mesothelioma Patients?

Two Phase III trials are actively enrolling first-line mesothelioma patients in 2026, each testing a different immunotherapy strategy against the current standard of care.^[3][8]

eVOLVE-Meso (NCT06097728) is the most significant actively recruiting trial. Sponsored by AstraZeneca, it evaluates volrustomig (MEDI5752), a bispecific antibody that simultaneously blocks both PD-1 and CTLA-4 in a single molecule—unlike nivolumab plus ipilimumab, which are two separate drugs. The trial randomizes approximately 825 patients globally to volrustomig plus carboplatin/pemetrexed versus investigator's choice of nivolumab plus ipilimumab or platinum/pemetrexed. Co-principal investigators are Dr. Marjorie Zauderer at Memorial Sloan Kettering and Dr. Arnaud Scherpereel at Lille University.^[3]

HIT-Meso (NCT05655078) is the first Phase III trial of proton beam therapy for mesothelioma, randomizing 148 patients to hemithoracic proton beam therapy versus active surveillance after definitive treatment. Proton beams can deliver higher radiation doses to the pleural surface while sparing the lung, heart, and liver. The trial is recruiting across 18–20 UK centers.^[10]

> "eVOLVE-Meso is the trial our clients ask about most. The idea of a single bispecific antibody replacing two separate immunotherapy drugs is intuitive—potentially fewer infusions and a different side effect profile. We're tracking enrollment closely and connecting eligible patients with participating sites." > — David Foster, Executive Director of Client Services, Danziger & De Llano

How Does ATOMIC-Meso Change Treatment for Non-Epithelioid Mesothelioma?

ATOMIC-Meso represents a breakthrough for the most aggressive mesothelioma subtypes. Published in JAMA Oncology in April 2024, this Phase 2/3 trial tested pegargaminase (ADI-PEG20) combined with chemotherapy versus chemotherapy alone in non-epithelioid pleural mesothelioma.^[2]

Outcome	Pegargaminase + Chemo	Placebo + Chemo	P-Value
Median Overall Survival	9.3 months	7.7 months	0.02
Median PFS	6.2 months	5.6 months	0.02
Hazard Ratio (OS)	0.71 (95% CI: 0.55–0.93)

The science is elegant. Non-epithelioid mesothelioma cells commonly lack the ASS1 enzyme, making them unable to synthesize arginine internally. Pegargaminase depletes arginine from the bloodstream, selectively starving ASS1-deficient tumor cells while normal cells compensate. This is one of the first targeted therapies designed specifically for mesothelioma's unique biology.^[2]

What Are the Side-by-Side Results of All 8 Key Trials?

The following comparison includes the eight most impactful mesothelioma trials informing treatment decisions in 2026. Trials range from completed studies with mature data to actively recruiting studies with preliminary or no efficacy results.^[1][7]

Trial	Treatment	Phase	Median OS	Key Finding
CheckMate 743 (5-yr)	Nivo + Ipi	III	18.1 mo	14% alive at 5 years; non-epithelioid HR 0.48
IND.227	Pembro + chemo	III	17.3 mo	62% ORR; alternative first-line option
ATOMIC-Meso	Pegargaminase + chemo	2/3	9.3 mo	First targeted therapy for non-epithelioid
eVOLVE-Meso	Volrustomig + chemo	III	Pending	Bispecific PD-1/CTLA-4; ~825 patients
Perioperative IO	Nivo ± Ipi (surgery)	II	28.6 mo*	36% recurrence-free; ctDNA biomarker
UV1 Vaccine (NIPU)	UV1 + pembro	II	Not reached*	31% ORR vs 16%; FDA Fast Track
CAR-T Intrapleural	Mesothelin CAR-T	I/II	Pending	Direct pleural delivery; dose expansion
HIT-Meso	Proton beam therapy	III	Pending	First Phase III proton trial for meso

*Perioperative OS is for the dual immunotherapy arm (Arm B) only. UV1 median OS had not been reached at interim analysis vs 10.7 months for control.

> "This comparison table is what I walk patients through in our initial consultations. Each trial addresses a different treatment challenge—from first-line therapy to surgery to second-line options. The key message is that the pipeline has never been deeper, and genetic profiling can now match individual patients to the trial most likely to benefit them." > — David Foster, Executive Director of Client Services, Danziger & De Llano

How Is Perioperative Immunotherapy Changing Surgical Mesothelioma Treatment?

A Johns Hopkins Phase 2 trial published in Nature Medicine in September 2025 provided the first evidence that immunotherapy before and after surgery can improve outcomes in resectable mesothelioma. Led by Dr. Valsamo Anagnostou, the trial evaluated two approaches in 30 patients.^[5]

Arm A (nivolumab alone before surgery): median PFS 9.6 months, median OS 19.3 months. Arm B (nivolumab plus ipilimumab before surgery): median PFS 19.8 months, median OS 28.6 months, with nearly 36% of patients alive and recurrence-free at follow-up.

A critical secondary finding: patients whose circulating tumor DNA (ctDNA) became undetectable after neoadjuvant therapy or declined by 95% or more had significantly longer event-free and overall survival. This establishes ctDNA as a potential real-time biomarker for predicting surgical mesothelioma outcomes.^[5]

What Targeted Therapies Are Available Based on Tumor Genetics?

The 2026 pipeline reflects a fundamental shift toward biomarker-matched therapy. Genetic profiling of a mesothelioma tumor can now open specific treatment pathways that were unavailable even two years ago.^[7]

Molecular Feature	Prevalence	Trial(s)	Drug Class
BAP1 loss	60–80%	Tazemetostat, Tulmimetostat, Olaparib	EZH2 inhibitor, PARP inhibitor
MTAP deletion	~25%	MRTX1719	PRMT5 inhibitor
NF2 mutation	~40%	SW-682, VT3989	TEAD inhibitor
Mesothelin overexpression	70–80%	CAR-T, CT-95, Sacituzumab	Cell therapy, ADC
ASS1 deficiency	Common (non-epithelioid)	ATOMIC-Meso	Arginine depletion
hTERT overexpression	80–90%	UV1 vaccine	Peptide vaccine

BAP1 loss is the most common actionable mutation in mesothelioma. When this tumor suppressor is lost, cancer cells become dependent on EZH2 activity, creating a synthetic lethality opportunity. The tazemetostat trial (NCT02860286) specifically enrolls BAP1-deficient patients, and tazemetostat is already FDA-approved for the related condition epithelioid sarcoma.^[7]

> "Genetic profiling is no longer optional for mesothelioma patients. A single tumor biopsy can now identify mutations that qualify you for multiple clinical trials you wouldn't otherwise know about. BAP1 testing alone opens three separate trial options. Every mesothelioma patient deserves comprehensive molecular testing." > — David Foster, Executive Director of Client Services, Danziger & De Llano

What Is CAR-T Cell Therapy and How Is It Being Tested for Mesothelioma?

CAR-T (chimeric antigen receptor T-cell) therapy engineers a patient's own immune cells to recognize and attack cancer. For mesothelioma, the primary target is mesothelin, a cell-surface protein overexpressed in 70–80% of epithelioid tumors.^[6]

The University of Pennsylvania trial (NCT04577326) represents the most advanced approach: autologous mesothelin-targeted CAR-T cells delivered directly into the pleural cavity rather than intravenously. This intrapleural delivery overcomes the tumor microenvironment challenges that limited earlier systemic CAR-T approaches. The trial is actively recruiting for dose expansion under investigators Dr. Dmitry Zeltsman and Dr. Regina Myers.^[6]

The EVEREST-2 trial (NCT06051695) takes a novel approach with logic-gated CAR-T technology. The A2B694 cells have dual receptors: an activator targeting mesothelin and a blocker recognizing HLA-A*02. In patients with tumor-specific HLA-A*02 loss, the CAR-T cells selectively kill tumor cells while sparing normal tissue that retains HLA-A*02—solving the on-target, off-tumor toxicity problem.^[7]

How Can Patients Find and Enroll in Mesothelioma Clinical Trials?

Finding the right clinical trial requires coordination between your oncology team, a mesothelioma attorney, and clinical trial matching resources. Key steps include:^[7][8]

Step 1: Get comprehensive molecular testing. Request BAP1, MTAP, NF2, and mesothelin testing from your biopsy sample. This single step can qualify you for multiple trials across different drug classes.

Step 2: Search active trials. ClinicalTrials.gov lists all registered studies. Filter by condition (mesothelioma), status (recruiting), and location. Your oncologist can interpret eligibility criteria.

Step 3: Understand financial support. Most trials cover the cost of the experimental treatment. Travel costs, lodging, and standard-of-care treatments may not be covered. Asbestos trust fund compensation and VA benefits can offset out-of-pocket expenses.

Step 4: Coordinate legal and medical timelines. Filing trust fund claims and lawsuits early preserves your legal rights regardless of which treatment path you pursue. Clinical trial participation does not affect your eligibility for compensation.

> "I tell every patient: don't choose between treatment and legal action. They run on parallel tracks. Your attorney files claims and preserves deadlines while your medical team pursues the best treatment option, whether that's standard immunotherapy or a cutting-edge clinical trial. The compensation you recover can fund travel to trial sites, experimental treatments, and family support." > — David Foster, Executive Director of Client Services, Danziger & De Llano

References

1. Scherpereel, A., et al. "Five-Year Overall Survival Update of CheckMate 743: First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma." Journal of Clinical Oncology, 2026. PubMed
2. Szlosarek, P.W., et al. "Pegargaminase Plus Chemotherapy in Non-Epithelioid Mesothelioma (ATOMIC-Meso)." JAMA Oncology, 2024. PubMed
3. ClinicalTrials.gov. "eVOLVE-Meso Phase III Trial — NCT06097728." ClinicalTrials.gov
4. Chu, Q., et al. "Pembrolizumab Plus Chemotherapy in Pleural Mesothelioma (IND.227)." The Lancet, 2023. PubMed
5. Anagnostou, V., et al. "Perioperative Nivolumab and Ipilimumab in Resectable Mesothelioma." Nature Medicine, 2025. PubMed
6. ClinicalTrials.gov. "Mesothelin-Targeted CAR-T Intrapleural Delivery — NCT04577326." ClinicalTrials.gov
7. NCI. "Malignant Mesothelioma Treatment — Patient Version." NCI
8. NCCN. "Malignant Pleural Mesothelioma: Clinical Practice Guidelines v2.2025." NCCN
9. NCI SEER. "Mesothelioma: SEER Stat Fact Sheets." SEER
10. ClinicalTrials.gov. "HIT-Meso Proton Beam Therapy — NCT05655078." ClinicalTrials.gov
11. ClinicalTrials.gov. "Sacituzumab Govitecan in Mesothelioma — NCT06477419." ClinicalTrials.gov
12. WikiMesothelioma. "Clinical Trials for Mesothelioma." WikiMesothelioma
13. WikiMesothelioma. "Mesothelioma Quick Facts." WikiMesothelioma
14. WikiMesothelioma. "Treatment Options Overview." WikiMesothelioma